Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -576.00M | 369.00M | 480.00M | 433.00M | 282.00M |
| Total Depreciation and Amortization | 241.00M | 239.00M | 260.00M | 249.00M | 251.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 910.00M | -31.00M | 189.00M | 248.00M | 30.00M |
| Change in Net Operating Assets | -164.00M | -617.00M | 229.00M | -561.00M | -336.00M |
| Cash from Operations | 411.00M | -40.00M | 1.16B | 369.00M | 227.00M |
| Capital Expenditure | -104.00M | -168.00M | -142.00M | -136.00M | -96.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -696.00M | -- | -- | -- | -- |
| Divestitures | 4.00M | 42.00M | 0.00 | 8.00M | 9.00M |
| Other Investing Activities | 305.00M | 355.00M | 307.00M | 263.00M | 323.00M |
| Cash from Investing | -491.00M | 229.00M | 165.00M | 135.00M | 236.00M |
| Total Debt Issued | -- | -- | 0.00 | -- | 2.31B |
| Total Debt Repaid | -- | -23.00M | 0.00 | -451.00M | -2.30B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00M | 36.00M | 40.00M | -2.00M | 1.00M |
| Cash from Financing | -1.00M | 13.00M | 40.00M | -453.00M | 6.00M |
| Foreign Exchange rate Adjustments | -5.00M | -17.00M | -10.00M | -9.00M | -5.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -86.00M | 185.00M | 1.35B | 42.00M | 464.00M |